LONDON, April 08, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (KNSA) (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for ...
The pericardium is the layer that surrounds the heart. The pericardium has two layers that work to lubricate the heart, protect it, and prevent it from filling up with too much blood. When this layer ...
Kiniksa Pharmaceuticals reports Q1 2025 net revenue of $137.8 million for ARCALYST, forecasts 2025 revenue of $590-$605 million. Kiniksa Pharmaceuticals reported significant financial growth in Q1 ...
– ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million – – ...
– Educational campaign to raise awareness of recurrent pericarditis and to empower patients to discuss ARCALYST with their healthcare provider – – Media accompanying this announcement is available by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results